Vienna

• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining Pending
  2025-523896-44-00 5 Congenital hemophilia A (HA)
• First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor Pending
  2025-524299-44-00 1 Glioblastoma
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• DIRECTION Study Pending
  2025-524495-39-00 6 Chronic Rhinosinusitis with Nasal Polyps
• Pharmacokinetics of Aztreonam-Avibactam in Critically Ill Patients with Sepsis Receiving ECMO Support: A Prospective PK Study Pending
  2025-524614-28-00 3 Sepsis
• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P … Pending
  2025-525009-18-00 5 Pancreatic Ductal Adenocarcinoma
• SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety stu … Pending
  2025-525091-29-00 4 Kidney Transplant Recipient
• LAFOV-Lung PET Pending
  2026-525834-45-00 1 Investigation in healthy volunteers
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting
  2025-522434-32-00 5 2026-07-01 Hemophilia A Without Inhibitors
• Venetoclax as treatment of acute graft-versus-host disease Recruiting
  2025-520545-74-00 4 2026-06-24 Acute graft-versus-host disease of the skin
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Recruiting
  2025-521390-14-00 4 2026-06-22 Acute Myeloid Leukemia
• A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) Recruiting
  2025-524894-17-00 10 2026-06-22 Neovascular age-related macular degeneration (NVAMD)
• Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Recruiting
  2024-516896-34-00 9 2026-06-17 progressive/relapsed/refractory pediatric low-grade glioma (pLGG)
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting
  2025-522435-33-00 5 2026-06-17 Hemophilia A
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-12 Uncontrolled Moderate to Severe Eosinophilic Asthma

Showing 49–72 of 834 trials